Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans

Therapeutic Drug Monitoring

Volumn 34, Issue 4, 2012, Pages 406-414

  Morand, Réjane ^a,b   Todesco, Liliane ^a,b   Donzelli, Massimiliano ^a,b   Fischer Barnicol, David ^c   Mullen, Peter J ^a,b   Krähenbühl, Stephan ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

carnitine; carnitine biosynthesis; OCTN2; valproate; valproylcarnitine

Indexed keywords

ACETYLCARNITINE; AMINO ACID TRANSPORTER; CARNITINE; CARNITINE DERIVATIVE; CARNITINE TRANSPORTER OCTN2; GAMMA BUTYROBETAINE; PROPIONYLCARNITINE; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROYLCARNITINE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; AMINO ACID TRANSPORT; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BLOOD LEVEL; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; HYPOCARNITINEMIA; IN VITRO STUDY; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME; URINARY EXCRETION;

ACETYLCARNITINE; ADULT; BETAINE; BIOLOGICAL TRANSPORT; CARNITINE; CELL LINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEK293 CELLS; HOMEOSTASIS; HUMANS; KIDNEY TUBULES, PROXIMAL; ORGANIC CATION TRANSPORT PROTEINS; VALPROIC ACID;

EID: 84863817216     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182608e2f     Document Type: Article

References (47)

1. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group. Neurology. 1997;48:182-188. (Pubitemid 27039539)
2. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016-1026. (Pubitemid 46436125)
3. Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord. 2010;124:228-234.
4. D'Amico D. Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. Neurol Sci. 2010;31(suppl 1):S23-S28.
5. DeVane CL. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol Bull. 2003;37(suppl 2):25-42.
6. Muro H, Tatsuhara T, Sugimoto T, et al. Determination of urinary valproylcarnitine by gas chromatography-mass spectrometry with selectedion monitoring. J Chromatogr B Biomed Appl. 1995;663:83-89.
7. Murakami K, Sugimoto T, Woo M, et al. Effect of L-carnitine supplementation on acute valproate intoxication. Epilepsia. 1996;37:687-689. (Pubitemid 26250003)
8. Millington DS, Bohan TP, Roe CR, et al. Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin Chim Acta. 1985;145:69-76. (Pubitemid 15117099)
9. Bohles H, Richter K, Wagner-Thiessen E, et al. Decreased serum carnitine in valproate induced Reye syndrome. Eur J Pediatr. 1982;139:185-186. (Pubitemid 13203679)
10. Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr. 1982;101:782-785. (Pubitemid 12006715)
11. Stumpf DA, Parker WD, Haas R. Carnitine deficiency with valproate therapy. J Pediatr. 1983;103:175-176. (Pubitemid 13073224)
12. Hamed SA, Abdella MM. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Epilepsy Res. 2009;86:32-41.
13. Eubanks AL, Aguirre B, Bourgeois JA. Severe acute hyperammonemia after brief exposure to valproate. Psychosomatics. 2008;49:82-83.
14. Thom H, Carter PE, Cole GF, et al. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol. 1991;33:795-802.
15. Coppola G, Epifanio G, Auricchio G, et al. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain Dev. 2006;28:358-365.
16. Hirose S, Mitsudome A, Yasumoto S, et al. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics. 1998;101:E9.
17. Silva MF, Selhorst J, Overmars H, et al. Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS. Clin Biochem. 2001;34:635-638. (Pubitemid 34159354)
18. Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta. 2000;1486:1-17. (Pubitemid 30336788)
19. Fritz I. The effect of muscle extracts on the oxidation of palmitic acid by liver slices and homogenates. Acta Physiol Scand. 1955;34:367-385.
20. Fritz IB, Marquis NR. The role of acylcarnitine esters and carnitine palmityltransferase in the transport of fatty acyl groups across mitochondrial membranes. Proc Natl Acad Sci U S A. 1965;54:1226-1233.
21. Brass EP, Hoppel CL. Relationship between acid-soluble carnitine and coenzyme A pools in vivo. Biochem J. 1980;190:495-504.
22. Friolet R, Hoppeler H, Krahenbuhl S. Relationship between the coenzyme A and the carnitine pools in human skeletal muscle at rest and after exhaustive exercise under normoxic and acutely hypoxic conditions. J Clin Invest. 1994;94:1490-1495. (Pubitemid 24309869)
23. Bremer J. Carnitine - metabolism and functions. Physiol Rev. 1983;63:1420-1480.
24. Vernez L, Dickenmann M, Steiger J, et al. Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. Nephrol Dial Transplant. 2006;21:450-458. (Pubitemid 43160002)
25. Heuberger W, Berardi S, Jacky E, et al. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol. 1998;54:503-508. (Pubitemid 28487369)
26. Krahenbuhl S, Brass EP, Hoppel CL. Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis. Hepatology. 2000;31:1217-1223. (Pubitemid 30351281)
27. Krahenbuhl S, Reichen J. Carnitine metabolism in patients with chronic liver disease. Hepatology. 1997;25:148-153. (Pubitemid 27015001)
28. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet. 1999;21:91-94. (Pubitemid 29036290)
29. Todesco L, Bur D, Brooks H, et al. Pharmacological manipulation of L-carnitine transport into L6 cells with stable overexpression of human OCTN2. Cell Mol Life Sci. 2008;65:1596-1608.
30. Haschke M, Vitins T, Lude S, et al. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant. 2010;25:426-433.
31. Vaz FM, Melegh B, Bene J, et al. Analysis of carnitine biosynthesis metabolites in urine by HPLC-electrospray tandem mass spectrometry. Clin Chem. 2002;48:826-834. (Pubitemid 34587581)
32. Stadler DD, Bale JF Jr, Chenard CA, et al. Effect of long-term valproic acid administration on the efficiency of carnitine reabsorption in humans. Metabolism. 1999;48:74-79. (Pubitemid 29035564)
33. Farkas V, Bock I, Cseko J, et al. Inhibition of carnitine biosynthesis by valproic acid in rats-the biochemical mechanism of inhibition. Biochem Pharmacol. 1996;52:1429-1433. (Pubitemid 26366368)
34. Ziegler HJ, Bruckner P, Binon F. O-acylation of dl-carnitine chloride. J Org Chem. 1967;32:3989-3991.
35. Todesco L, Bodmer M, Vonwil K, et al. Interaction between pivaloylcarnitine and L-carnitine transport into L6 cells overexpressing hOCTN2. Chem Biol Interact. 2009;180:472-477.
36. Vernez L, Hopfgartner G, Wenk M, et al. Determination of carnitine and acylcarnitines in urine by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. J Chromatogr A. 2003;984:203-213. (Pubitemid 35454085)
37. Vernez L, Wenk M, Krahenbuhl S. Determination of carnitine and acylcarnitines in plasma by high-performance liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18:1233-1238. (Pubitemid 38702390)
38. Rebouche CJ, Paulson DJ. Carnitine metabolism and function in humans. Annu Rev Nutr. 1986;6:41-66.
39. Stieger B, O'Neill B, Krahenbuhl S. Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. Biochem J. 1995;309(pt 2):643-647.
40. Tamai I, Ohashi R, Nezu J, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem. 1998;273:20378-20382. (Pubitemid 28377603)
41. Lombard KA, Olson AL, Nelson SE, et al. Carnitine status of lactoovovegetarians and strict vegetarian adults and children. Am J Clin Nutr. 1989;50:301-306. (Pubitemid 19208747)
42. Schurch R, Todesco L, Novakova K, et al. The plasma carnitine concentration regulates renal OCTN2 expression and carnitine transport in rats. Eur J Pharmacol. 2010;635:171-176.
43. Maeda T, Wakasawa T, Funabashi M, et al. Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha. Biol Pharm Bull. 2008;31:1230-1236. (Pubitemid 351871185)
44. Ringseis R, Posel S, Hirche F, et al. Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate causes upregulation of organic cation transporter 2 in liver and small intestine of rats. Pharmacol Res. 2007;56:175-183. (Pubitemid 47302802)
45. Hawkins JM, Jones WE, Bonner FW, et al. The effect of peroxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney. Drug Metab Rev. 1987;18:441-515.
46. Horie S, Suga T. Enhancement of peroxisomal beta-oxidation in the liver of rats and mice treated with valproic acid. Biochem Pharmacol. 1985;34:1357-1362. (Pubitemid 15025769)
47. Ohnishi S, Okamura N, Sakamoto S, et al. Role of Na+/L-carnitine transporter (OCTN2) in renal handling of pivaloylcarnitine and valproylcarnitine formed during pivalic acid-containing prodrugs and valproic acid treatment. Drug Metab Pharmacokinet. 2008;23:293-303.